Study of sacituzumab govitecan for advanced salivary gland and thyroid cancers
Treatments studied
Part of Cancer, Hormones & metabolism, Mouth & dental clinical trials.
This trial tests a drug called sacituzumab govitecan in people with advanced salivary gland cancer or thyroid cancer that has spread or cannot be removed. The goal is to see if the drug can help shrink or slow down the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 21 years old.
- You must have advanced salivary gland or thyroid cancer that has spread or cannot be removed, and standard treatments are not an option.
- Your cancer must have grown in the last 6 months (for salivary gland) or 13 months (for thyroid cancer) despite prior treatment.
- You must be in good physical condition (able to do daily activities without help).
- You must not have untreated brain or spinal cord spread of cancer.
- You must be willing to provide blood and possibly a new tumor sample for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests sacituzumab govitecan, an anti-cancer medicine, in people with recurrent or metastatic (coming back or spread) secretory gland cancers or related salivary gland cancers. It aims to see how well the treatment can shrink tumors and control disease when surgery or radiation is not a cure.
This trial tests a new drug called sacituzumab govitecan for people with advanced thyroid cancer that has stopped responding to standard treatments. It may be an option for those with differentiated thyroid cancer (after certain prior therapies) or anaplastic thyroid cancer (first-line or after one prior treatment).
This trial tests a drug called sacituzumab govitecan for people with advanced thymic cancer (thymoma or thymic carcinoma) that has not responded to previous treatments. The goal is to see if the drug can shrink or slow the growth of the cancer.
This trial tests a drug called sacituzumab govitecan for people with advanced esophageal squamous cell carcinoma that has already been treated with chemotherapy and immunotherapy. The drug targets a protein called Trop-2 on cancer cells to try to stop tumor growth.
This trial tests a combination of two drugs—sacituzumab govitecan and cetuximab—for people with advanced head and neck cancer that has gotten worse after immunotherapy. The goal is to see if this new treatment can shrink or slow the cancer.
This study is testing a drug called sacituzumab govitecan (SG) for people with advanced triple-negative breast cancer who have already had other treatments. The goal is to see how well the drug works and what side effects it causes, using your tumor samples to look for clues (biomarkers).
Hear when a new Salivary Gland Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.